aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company, announced its upcoming addition to both the Russell 2000® Index and Russell 3000® Index, effective after market close on June 27, 2025.
The Russell 3000® Index serves as a key benchmark for the U.S. equity market, tracking the 3,000 largest publicly traded U.S. companies, while the Russell 2000® Index specifically focuses on small-cap companies. This inclusion, which lasts for one year, will result in automatic inclusion in corresponding growth and value style indexes.
aTyr Pharma (Nasdaq: ATYR), un'azienda biotecnologica in fase clinica, ha annunciato la sua prossima inclusione sia nel Russell 2000® Index che nel Russell 3000® Index, a partire dalla chiusura del mercato del 27 giugno 2025.
Il Russell 3000® Index rappresenta un importante punto di riferimento per il mercato azionario statunitense, monitorando le 3.000 maggiori società quotate negli USA, mentre il Russell 2000® Index si concentra specificamente sulle società a piccola capitalizzazione. Questa inclusione, valida per un anno, comporterà l'inclusione automatica negli indici di stile crescita e valore corrispondenti.
aTyr Pharma (Nasdaq: ATYR), una empresa biotecnológica en etapa clínica, anunció su próxima incorporación tanto al Russell 2000® Index como al Russell 3000® Index, efectiva después del cierre del mercado el 27 de junio de 2025.
El Russell 3000® Index es un referente clave para el mercado de acciones de EE.UU., rastreando las 3,000 mayores compañías públicas estadounidenses, mientras que el Russell 2000® Index se centra específicamente en empresas de pequeña capitalización. Esta inclusión, que dura un año, resultará en la incorporación automática a los índices de estilo de crecimiento y valor correspondientes.
aTyr Pharma (나스닥: ATYR)는 임상 단계의 생명공학 회사로, 2025년 6월 27일 장 마감 후부터 러셀 2000® 지수와 러셀 3000® 지수에 각각 편입될 예정임을 발표했습니다.
러셀 3000® 지수는 미국 주식시장의 주요 벤치마크로, 미국에서 가장 큰 3,000개 상장 기업을 추적하며, 러셀 2000® 지수는 특히 소형주에 초점을 맞춥니다. 이 편입은 1년간 유효하며, 이에 따라 해당 성장 및 가치 스타일 지수에도 자동으로 포함됩니다.
aTyr Pharma (Nasdaq : ATYR), une société biotechnologique en phase clinique, a annoncé son intégration prochaine au Russell 2000® Index et au Russell 3000® Index, effective après la clôture du marché le 27 juin 2025.
Le Russell 3000® Index est un indice de référence clé pour le marché boursier américain, suivant les 3 000 plus grandes entreprises cotées aux États-Unis, tandis que le Russell 2000® Index se concentre spécifiquement sur les petites capitalisations. Cette inclusion, valable un an, entraînera une inclusion automatique dans les indices de style croissance et valeur correspondants.
aTyr Pharma (Nasdaq: ATYR), ein biotechnologisches Unternehmen in der klinischen Phase, gab seine bevorstehende Aufnahme sowohl in den Russell 2000® Index als auch den Russell 3000® Index bekannt, wirksam nach Börsenschluss am 27. Juni 2025.
Der Russell 3000® Index dient als wichtiger Maßstab für den US-Aktienmarkt und verfolgt die 3.000 größten börsennotierten US-Unternehmen, während sich der Russell 2000® Index speziell auf Small-Cap-Unternehmen konzentriert. Diese einjährige Aufnahme führt automatisch zur Aufnahme in die entsprechenden Wachstums- und Value-Stilindizes.
- Inclusion in Russell indexes increases visibility to institutional investors
- Potential for increased trading volume and liquidity
- Enhanced market exposure through index fund inclusion
- Recognition of company's market capitalization growth
- None.
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution.
The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000® Index is a subset of the Russell 3000® Index that tracks small-cap companies in the U.S. equities market. Membership in the Russell Indexes lasts for one year and results in automatic inclusion in appropriate growth and value style indexes. FTSE Russell determines membership for its Russell Indexes primarily by objective, market-capitalization rankings and style attributes. The Russell Indexes are used by investment managers and institutional managers for index funds and as benchmarks for active investment strategies. Russell Indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell Indexes and the annual reconstitution, visit the “Russell Reconstitution” section on the FTSE Russell website.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as "anticipate," “believes,” “designed,” “could,” “can,” “expects,” “intends,” “may,” “plans,” “potential,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding the Company’s expected inclusion in the Russell 2000® and 3000® Indexes; and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of efzofitimod, the risks associated with clinical trials generally, the risk that future findings may not reflect the findings from the interim analysis discussed above, the risk that we or our partners may cease or delay preclinical or clinical development activities for efzofitimod for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
When will aTyr Pharma (ATYR) be added to the Russell 2000 and Russell 3000 indexes?
What are the benefits for aTyr Pharma of joining the Russell indexes?
How long will aTyr Pharma remain in the Russell indexes?
What is aTyr Pharma's main business focus?
